+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
FEMALE
ID07724106

Evaluating Safety and Immune Response of the NeoOVSV Vaccine with Chemotherapy and PD-1 Antibody in Women with Stage IIIII Ovarian Cancer After Surgery

Led by West China Hospital · Updated on 2026-09-09

9

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and preliminary effects of the NeoOVSV mRNA-lipid nanoparticle vaccine in patients with stage II or III ovarian cancer after surgery. This Phase I, single-arm, open-label study involves a dose-escalation design to find the recommended vaccine dose when combined with standard adjuvant chemotherapy and a PD-1 antibody called tislelizumab. The study focuses on patients who have undergone surgical tumor removal but have not yet started other adjuvant therapies. Participants will receive one of three dose levels of the NeoOVSV vaccine 25, 50, or 100 micrograms by intramuscular injection, starting about 4 weeks after surgery. The vaccine is given in a priming phase with 6 doses every 3 weeks during chemotherapy, followed by a booster phase of 3 weekly doses after chemotherapy ends. Alongside the vaccine, patients receive standard chemotherapy and six doses of tislelizumab, a PD-1 antibody, generally administered before chemotherapy. During the study, participants will be monitored closely for safety, including adverse events and dose-limiting toxicities within 28 days after vaccination. Blood samples will be collected to assess immune responses, and clinical activity will be evaluated by disease-free survival, imaging, tumor markers, and circulating tumor DNA. The study will also assess feasibility related to vaccine production, delivery, and treatment completion. Participants will be followed for survival and long-term safety until death, study closure, or end of follow-up, with the entire participation lasting up to 24 months post-surgery.

CONDITIONS

Brief Title

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery

Research Team

N

Nan Lin, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here